Slideshows Images Quizzes

Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. See additional information.


Last reviewed on RxList: 7/24/2020
Pazeo Side Effects Center

What Is Pazeo?

Pazeo (olopatadine hydrochloride) Ophthalmic Solution is a mast cell stabilizer used to treat ocular (eye) itching associated with allergic conjunctivitis.

What Are Side Effects of Pazeo?

Common side effects of Pazeo include:

  • blurred vision,
  • dry eye,
  • watery eyes,
  • superficial inflammation of the cornea,
  • distorted or bitter sense of taste,
  • sore throat,
  • stinging or burning in the eye,
  • abnormal sensation in the eye,
  • eye sensitivity to bright light, or
  • bloodshot eyes.

Dosage for Pazeo

The recommended dosage of Pazeo is to instill one drop in each affected eye once a day.

What Drugs, Substances, or Supplements Interact with Pazeo?

Pazeo may interact with other drugs. Tell your doctor all medications and supplements you use.

Pazeo During Pregnancy and Breastfeeding

During pregnancy, Pazeo should be used only if prescribed. It is unknown if this drug passes into breast milk when used in the eye. Consult your doctor before breastfeeding.

Additional Information

Our Pazeo (olopatadine hydrochloride) Ophthalmic Solution Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.


Could I Be Allergic? Discover Your Allergy Triggers See Slideshow
Pazeo Professional Information


Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

In a randomized, double-masked, vehicle-controlled trial, patients at risk for developing allergic conjunctivitis received one drop of either PAZEO (N=330) or vehicle (N=169) in both eyes for 6 weeks. The mean age of the population was 32 years (range 2 to 74 years). Thirty-five percent were male. Fifty-three percent had brown iris color and 23% had blue iris color. The most commonly reported adverse reactions occurred in 2-5% of patients treated with either PAZEO or vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia and abnormal sensation in eye.

Read the entire FDA prescribing information for Pazeo (Olopatadine Hydrochloride Ophthalmic Solution)


Allergies can best be described as: See Answer
Related Resources for Pazeo

Related Health

© Pazeo Patient Information is supplied by Cerner Multum, Inc. and Pazeo Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors